Artisan Red Premium: New Special Body Color Developed by Mazda

HIROSHIMA, Japan, Nov 15, 2022 - (JCN Newswire via SEAPRWire.com) - Mazda Motor Corporation has applied its proprietary painting technology Takuminuri(1) to develop a new special color Artisan Red Premium. This color will be introduced as a premium highlight for vehicles in our current lineups as well as forthcoming releases in our Large Product group.Artisan Red Premium Paint Layer StructureMazda believes color to be a crucial element of what gives form to a vehicle; thus, we are focusing our efforts on developing colors that accentuate a dynamic and delicate expression in line with the Kodo - Soul of Motion - design theme. Artisan Red Premium, the fourth Takuminuri color, was developed to extend the range of how the world views red, one of the colors symbolizing Mazda, as a culmination of the Takuminuri evolution to mark the 10th year since the first color Soul Red Premium was released.Artisan Red Premium conveys the connotation of a red color created by skilled artisans. This extraordinary red produced by Mazda designers, engineers and other artisans manifests a mature outlook that is more refined and sophisticated than previous special colors. The concept underlying design was to create the red found in a mature wine made with unsurpassed craftsmanship. Artisan Red Premium accentuates the strength and beauty of form that takes shape as highlights hit by light portray a fine-grained transparent red shining brightly and dominant shade produces a profound depth and richness, rendering high contrast.Also, similar to Soul Red Crystal(2), Artisan Red Premium is comprised of three layers: a clear layer, translucent paint layer, and a reflective/absorptive layer. It combines an outstanding aesthetic appearance with a reduced environmental footprint. For the translucent paint layer, a high-chroma pigment is employed that people perceive to be the reddest of reds, a pigment also used for the Soul Red Crystal. For the reflective/absorptive layer, we applied a technology that more smoothly aligns aluminum flakes at regular intervals. This was also leveraged for the third Takuminuri color Rhodium White Premium. In addition, we improved on the jet-black pigment, which renders shade in the second color Machine Gray. This combination of technologies developed over a period of 10 years conveys brightness in highlights produced by strong reflection and the richness of shades created as light is soundly absorbed so as to achieve a balance between transparency and a mature profoundness.In the belief that "color is an element of form," Mazda will continue to pursue new color expressions and painting technologies to enhance the attractiveness of our products, aiming to be a company that shares a special bond with its customers.(1) Takuminuri, which translates as "Artisan coloring," is Mazda's painting technology that reproduces a precise, high-quality paint finish as if applied by the hands of a skilled craftsman along the automobile mass production line.(2) Soul Red Crystal is a further refinement of Soul Red Premium and a special paint color developed with the Takuminuri painting technology. Copyright 2022 JCN Newswire. All rights reserved. (via SEAPRWire)

InaVac gets emergency approval from BPOM

Surabaya, East Java, Indonesia, Nov 14, 2022 - (ACN Newswire via SEAPRWire.com) - The Food and Drug Supervisory Agency (BPOM) has issued emergency use authorization (EUA) for InaVac, a COVID-19 vaccine developed by researchers from Airlangga University (Unair).InaVac, COVID-19 vaccine, is developed by the University of Airlangga in Surabaya, East Java Province. (ANTARA/HO-BPBRIN Unair)"InaVac has obtained emergency use authorization from BPOM and will be mass-produced," the rector of Unair, Prof. Moh. Nasih, said on the sidelines of the campus' dies natalis (anniversary) on Wednesday.The vaccine, which can be used to prevent a COVID-19 infection, has been made using an inactivated virus, which means, a virus that cannot reproduce and cause disease.InaVac has been approved for use as a primary vaccine for people aged 18 and above for boosting immunity levels.According to Nasih, the vaccine was developed as part of an effort by the university to significantly contribute to and impact the health sector.Following the provision of EUA from BPOM, he expressed his gratitude to various stakeholders that have supported the development of the vaccine."Thank you to the Ministry of Health for providing support in the form of large amounts of funding; the provincial government has also provided extraordinary support," he remarked."Dr. Soetomo Hospital has also been very supportive. Equally important has been the role of Unair researchers who worked hard for this," he added.Former state-owned enterprises minister Dahlan Iskan also expressed his pleasure over the completion of the domestically-made COVID-19 vaccine."I am happy because Unair has processed this vaccine to completion. How this vaccine was successfully launched, how to find people who want to undergo the vaccine. Finding people who are willing to be clinically tested is extremely difficult but Unair managed to finish it," he said.It is hoped that after InaVac, more vaccines will be produced through continued research and development so that they can answer future challenges and problems.Unair is currently developing a booster vaccine and a COVID-19 vaccine for children."The news about vaccines has been very encouraging; hopefully, later booster vaccines and children can be produced," he said.For further information, please visit: https://www.unair.ac.id/Written by: Abdul Hakim, Yashinta Difa, Editor: Fardah Assegaf (c) ANTARA 2022 Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)

Fujitsu and Hokuhoku Financial Group develop algorithm for efficient flood risk calculation for Task Force on Climate-related Financial Disclosures (TCFD) reporting

TOKYO, Jul 28, 2022 - (JCN Newswire via SEAPRWire.com) - Fujitsu and Hokuhoku Financial Group, Inc. (hereinafter Hokuhoku FG)(1) today announced the development of an algorithm to support information disclosure in line with the recommendations of the Task Force on Climate-related Financial Disclosures (hereinafter TCFD)(2). The two companies conducted trial demonstrations and confirmed the efficiency of the new algorithm in supporting customers in improving their operational efficiency when preparing for TCFD reporting.The new algorithm developed by Fujitsu automatically arranges customer data and hazard data issued by the government on a map to calculate the physical risk of a customer or asset in the event of a flood. The analysis results will be used in the integrated report of Hokuhoku FG that will be issued on July 29, 2022.Moving forward, the two companies will continue to verify the effectiveness of the newly developed algorithm for customers in the financial industry with a large number of clients, and plan to expand it to customers in other industries in the future.BackgroundClimate change poses a major, ongoing economic threat, and not only listed companies but also many affiliated companies are increasing their efforts to resolve the myriad issues related to global warming. Underlining the growing significance of this responsibility, players in various industries increasingly focus on TCFD as a measure to disclose climate-related financial information.In Japan, since April 2022, companies listed on the Tokyo Stock Exchange's Prime Market are required to disclose TCFD information, and the impact of climate-related risks on companies and their measures to mitigate its impacts have been attracting growing attention. Companies situated in flood-prone areas are especially vulnerable, as they are continuously exposed to significant risks that can affect the continuity of their business.The implementation of cross-industry measures that also include players such as logistics companies that transport goods and institutions that finance climate change initiatives represent an ongoing task.To address this issue, Fujitsu and Hokuhoku FG developed new measures to accurately and efficiently measure flood risks, which represent a high-priority issue within climate-related risks.Outline of the trial demonstrationsFujitsu and Hokuhoku FG conducted trial demonstrations of the newly developed algorithm from November 2021 to March 2022 for real estate collateral of the Hokuriku Bank and the Hokkaido Bank. Leveraging Fujitsu's IT technology and Hokuhoku FG's knowledge of risk management practices, the two companies systematized a process to plot customers' properties on a hazard map and predict potential flood risks. As a result, Hokuhoku FG employees were able to streamline approximately 850 hours of manual work time and to improve efficiency in their preparation for TCFD reporting. The two companies further confirmed the effectiveness of the newly developed algorithm in correctly measuring flood risks.Future PlansWith the aim to become an environmentally advanced financial group, Hokuhoku FG will utilize its broad customer base to explore new services that support suppliers' efforts to realize their ESG/SDGs related objectives and decarbonization.Fujitsu will continue verifications of the newly developed algorithm starting with the financial sector where it expects to generate strong interest. Fujitsu further plans to combine this algorithm with initiatives aimed at reducing CO2 emissions of industries including the logistics industry, which remains one of the most important areas in which society's infrastructure faces disruption by potential flood risks. Both Fujitsu and Hokuhoku FG will continue their efforts to contribute to the sustainable development of local economies and communities.(1) Hokuhoku Financial Group, Inc. :Headquarters: Toyama Prefecture, Toyama City; President: Hiroshi Nakazawa(2) TCFD: "Task Force on Climate-related Financial Disclosures" - Disclosure in line with the recommendations of the Task Force on Climate-related Financial Disclosures. Established by the Financial Stability Board (FSB) to examine how to conduct climate-related disclosure and respond to financial institutions. Companies listed on the Tokyo Stock Exchange's Prime Market are required to disclose information on climate change-related risks and opportunities in line with TCFD recommendations.About FujitsuFujitsu's purpose is to make the world more sustainable by building trust in society through innovation. As the digital transformation partner of choice for customers in over 100 countries, our 124,000 employees work to resolve some of the greatest challenges facing humanity. Our range of services and solutions draw on five key technologies: Computing, Networks, AI, Data & Security, and Converging Technologies, which we bring together to deliver sustainability transformation. Fujitsu Limited (TSE:6702) reported consolidated revenues of 3.6 trillion yen (US$32 billion) for the fiscal year ended March 31, 2022 and remains the top digital services company in Japan by market share. Find out more: www.fujitsu.com. Copyright 2022 JCN Newswire. All rights reserved. (via SEAPRWire)

Eisai Listed for 21st Consecutive Year in FTSE4Good Index Series

TOKYO, Jul 26, 2022 - (JCN Newswire via SEAPRWire.com) - Eisai Co., Ltd. announced today that it has been included in the FTSE4Good Index Series for the 21st consecutive year since its initial inclusion in 2002. The FTSE4Good Index Series is a global index series for socially responsible investment.The FTSE4Good Index Series was developed by FTSE Russell to promote investment in companies that meet global environmental, social and governance (ESG) standards. Eisai received particularly high scores in "Corporate Governance", "Customer Responsibility", "Labor Standards" and "Tax Transparency", among others. As of the end of June 2022, 1,092 companies worldwide and 224 Japanese companies were included in the FTSE4Good Developed Index Series.Currently, in addition to the MSCI ESG Leaders Indexes, another global ESG investment index, Eisai is also listed in the FTSE Blossom Japan Index, the FTSE Blossom Japan Sector Relative Index, the MSCI Japan ESG Select Leaders Index, the MSCI (WIN) and the S&P/JPX Carbon Efficient Index, which are ESG investment indices for Japanese stocks Japan Empowering Women Index adopted by the Government Pension Investment Fund (GPIF).Eisai's corporate concept is to give first thought to patients and people in the daily living domain, and to increase the benefits that health care provides to them, as well as address diverse healthcare needs worldwide. By strengthening its ESG initiatives and increasing non-financial value, Eisai is striving to sustainably enhance corporate value based on this concept.For more information on our ESG initiatives, please visit www.eisai.com/sustainability/index.html.Media Inquiries:Public Relations DepartmentEisai Co., Ltd. +81-(0)3-3817-5120 Copyright 2022 JCN Newswire. All rights reserved. (via SEAPRWire)

Toyota and Suzuki to Deepen Collaboration in the Fields of Development and Production in India

TOKYO, Jun 24, 2022 - (JCN Newswire via SEAPRWire.com) - Toyota Motor Corporation (Toyota) and Suzuki Motor Corporation (Suzuki) signed a memorandum of understanding for a business alliance in 2017. Since then, the two companies have been bringing together Toyota's strength in electrification technologies and Suzuki's strength in technologies for compact vehicles for joint collaboration in production and in the widespread popularization of electrified vehicles.Toyota and Suzuki are promoting mutual supply of vehicles globally, which is one of the collaborations in the business partnership, and the two companies will now start production of a new SUV model developed by Suzuki at Toyota Kirloskar Motor Pvt. Ltd. (TKM) from August. Maruti Suzuki India Limited and TKM will market the new model in India as Suzuki and Toyota models, respectively. Furthermore, the two companies are planning to export the new model to markets outside India including Africa.The powertrains of the new model to be on sale in India, will be equipped with mild hybrid developed by Suzuki and strong hybrid developed by Toyota. By bringing together strengths of both Toyota and Suzuki through the collaboration, the two companies will be able to provide a wide variety of vehicle electrification technologies to customers and contribute to the acceleration of electrification and the realization of a carbon-neutral society in India.Including investment in expansion of collaboration in India, Toyota and Suzuki will remain committed to the achievement of the "Make in India" initiative promoted by the Indian government, and contribute to sustainable economic growth and to the vision of achieving net zero GHG emissions by 2070.Toyota President Akio Toyoda said: "We are pleased to announce the new SUV with Suzuki, a company that has a long history of local involvement in the Indian business. Today, the automotive industry is facing various challenges such as electrification and carbon neutrality. By leveraging the respective strengths of Toyota and Suzuki to provide Indian customers with a variety of options, we hope to contribute to the reduction of CO2 emissions and realize a society where 'no-one is left behind' and 'everyone can move freely.'"Suzuki President Toshihiro Suzuki said: "Production of the new SUV at TKM is a project that can contribute to the growth of India through providing eco-friendly mobility needed by customers. We recognize that it is a big milestone toward further deepening our collaboration in the future. We appreciate the support from Toyota, and at the same time, will explore new synergy and business opportunities through continuous collaboration." Copyright 2022 JCN Newswire. All rights reserved. (via SEAPRWire)

Biolidics to Commence Commercial Production of its ClearEpi SARS-COV-2 Neutralising Antibody Rapid Test Kit

Singapore, Dec 9, 2021 - (ACN Newswire via SEAPRWire.com) - Biolidics Limited ("Biolidics" or the "Company" and together with its subsidiaries, the "Group"), a medical technology company with a focus on innovative diagnostic solutions, is pleased to announce that it had on 8 December 2021: (i) entered into a definitive agreement with its contract manufacturer for the production of the ClearEpi NAB Test; and (ii) obtained the relevant product liability insurance for the ClearEpi NAB Test. The ClearEpi NAB Test was developed by Biolidics with technology licensed from A*STAR's A*ccelerate.Highlights:- Biolidics has entered into a definitive manufacturing agreement for the production of its ClearEpi SARS-CoV-2 Neutralising Antibody Rapid Test Kit (the "ClearEpi NAB Test") and obtained the relevant product liability insurance- Unlike most commercially available COVID-19 serology tests which test for IgM/ IgG antibodies in patients, the ClearEpi NAB Test, developed by Biolidics with technology licensed from the Agency for Science, Technology and Research ("A*STAR")'s Accelerate Technologies Pte Ltd ("A*ccelerate"), provides results that may indicate an individual's protective immunity against COVID-19- Neutralising antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection(1)- The ClearEpi NAB Test can potentially serve as an important tool to assist in the area of assessing vaccine efficacy, vaccine deployment and social activities management (such as air travel(2)), among others- The commercialisation of ClearEpi NAB Test is another Singapore medical technology innovation that showcases the strong collaborative partnerships between Singapore public agencies and the private sector- The ClearEpi NAB Test has obtained the CE marking that allows it to be marketed and sold in the European UnionThe commercial production for the ClearEpi NAB Test by the Company is expected to commence in the current financial year ending 31 December 2021.The clinical validation of the ClearEpi NAB Test was undertaken in Singapore. Biolidics engaged A*STAR Infectious Disease Labs (ID Labs) for the screening of the prototype, as part of the clinical validation of the ClearEpi NAB Test conducted by Biolidics. ID Labs is an A*STAR research institute set up in April 2021 to undertake disease-specific research efforts within A*STAR. On 20 September 2021, the Group announced that it has developed the ClearEpi NAB Test that is intended for qualitative detection of neutralising antibodies in serum or plasma which provides an indication of the individual's protective immunity against COVID-19 infection(1),(3).Most commercially available serology tests against COVID-19, including the Company's COVID-19 Antibody Test Kit launched on 30 March 2020, test for the presence of IgM/IgG antibodies. The presence of IgM/IgG antibodies indicates whether an individual has been previously infected. Not all antibodies have neutralising or "disarming" capacity.Neutralising antibodies, on the other hand bind to regions of the virus that "disarm" or prevent infection directly. The presence of neutralising antibodies provides indications that an individual has protective immunity against infection1,3. Nonetheless, it is important to note that information is still emerging from researches in relation to the level of antibodies sufficient to confer protective immunity to an individual, and how long such protective immunity against COVID-19 may last in an individual.In addition, the Group announced on 20 September 2021 that it had received confirmation for the CE marking for the ClearEpi NAB Test which enables the Company to market and sell the ClearEpi NAB Test in the European Union.Mr. Song Tang Yih, Executive Director and Chief Executive Officer of Biolidics, said, "As the COVID-19 pandemic becomes endemic, we believe that our ClearEpi NAB Test canbecome a vital tool in assessing vaccine candidates and formulate vaccine deployment strategies (such as the need for additional booster doses). With our ClearEpi NAB Test, the testing of neutralising antibodies may also serve as a guide for government agencies to accelerate the re-opening of the economy, social activities and global travel."This document is to be read in conjunction with Biolidics' exchange filings on 8 December 2021, which can be downloaded via www.sgx.com.About Biolidics Limited(Bloomberg Code: BLD: Singapore / Reuters Code: BIOL.SI / SGX Code: 8YY)Incorporated in 2009, Biolidics Limited is a precision medicine medical technology company with a focus in developing a portfolio of innovative diagnostic solutions to lower healthcare costs and improve clinical outcomes.Biolidics has developed and commercialised the ClearCell FX1 System, a fully automated CE- IVD medical device which relies on a novel, patented technology to separate and enrich cancer cells from blood, allowing users of the system to perform liquid biopsies to test for the presence of cancer cells (specifically circulating tumour cells, or CTCs) in blood samples or perform further analysis on cancer cells.Liquid biopsies (i.e. analysis of the CTCs in blood samples) have many applications throughout the various stages of a patient's cancer journey, from cancer screening and staging to personalised treatment, and post-cancer monitoring.Biolidics also has a CAP accredited clinical laboratory in Singapore that offers a wide range of tests, which could potentially accelerate its revenue growth and execution of its business strategy in cancer diagnostics.In addition, Biolidics has formed an infectious diseases division to develop certified test kits with various diagnostic partners.Biolidics' quality assurance capabilities have been recognised through its ISO 13485 certification, CE-IVD, US FDA Class I registration and NMPA Class I registration.For additional information, please visit www.biolidics.com.This press release has been prepared by Biolidics Limited (the "Company") and has been reviewed by the Company's sponsor, United Overseas Bank Limited (the "Sponsor"), for compliance with Rules 226(2)(b) and 753(2) of the Singapore Exchange Securities Trading Limited (the "SGX-ST") Listing Manual Section B: Rules of Catalist. This press release has not been examined or approved by the SGX- ST. The SGX-ST assumes no responsibility for the contents of this press release, including the correctness of any of the statements or opinions made or reports contained in this press release.The contact person for the Sponsor is Mr. Lim Hoon Khiat, Director, Equity Capital Markets, who can be contacted at 80 Raffles Place, #03-03 UOB Plaza 1, Singapore 048624, telephone: +65 6533 9898.(1) go.nature.com/31HbCSv(2) bit.ly/3EEnO4G(3) bit.ly/3oyqv26Issued on behalf of Biolidics Limited by 8PR Asia Pte Ltd.Media & Investor Contacts:Mr. Alex TANMobile: +65 9451 5252Email: alex.tan@8prasia.com Copyright 2021 ACN Newswire. All rights reserved. (via SEAPRWire)

Bitcoin Latinum (LTNM) Launches on DigiFinex rising 200% in first hour of trading

PALO ALTO, CA, Oct 27, 2021 - (ACN Newswire via SEAPRWire.com) - Bitcoin Latinum (LTNM), the next generation, insured, asset-backed cryptocurrency, has officially listed on the DigiFinex exchange, opening over 200% in its first hour of trading. Bitcoin Latinum congratulates DigiFinex on a successful launch, and everyone who has supported the project.Monsoon Blockchain, Bitcoin Latinum's lead developer, has announced plans for Bitcoin Latinum to officially list on seven top-tier public exchanges, under the ticker LTNM. In addition to DigiFinex, the exchanges are: HitBTC (the fifth largest exchange by volume at $4 billion), FMFW (formerly Bitcoin.com and operating with $3.3 billion in daily trading volume), Changelly ($2.71 billion in daily volume), Changelly Pro, Bitmart ($1.6 billion in daily volume), and XT.com by the end of 2021.Headquartered in Singapore, DigiFinex boasts over 4 million users across the globe, and can be accessed by users in 150 countries. With daily trading volume around $1 billion, DigiFinex is one of the top rated global cryptocurrency exchanges that offers spot, leverage, perpetual trading, and fiat to crypto trading. In addition, DigiFinex offers unparalleled 24/7 customer service for its user base. For more information about DigiFinex, please visit https://www.digifinex.com/Bitcoin Latinum was built as an open-architecture cryptocurrency technology, capable of handling large transaction volume, cybersecurity, and digital asset management. Based on the Bitcoin ecosystem, Bitcoin Latinum was developed by Monsoon Blockchain Corporation on behalf of the Bitcoin Latinum Foundation. LTNM is a greener, faster, and more secure version of Bitcoin, and is poised to revolutionize digital transactions.Unlike other crypto assets, LTNM is insured, and backed by real-world and digital assets. Its asset backing is held in a fund model, so that base asset value increases over time. It accelerates this asset-backed funds growth by depositing 80% of the transaction fee back into the asset fund that backs the currency. Thus, the more Bitcoin Latinum is adopted, the faster its asset funds grow, creating a self-inflating currency. The listing on DigiFinex highlights Bitcoin Latinum Foundation's commitment to supporting the growth of a sustainable crypto ecosystem.Bitcoin Latinum was developed with a highly scalable network that will initially support up to 10,000 transactions per second and millions of transactions per day to facilitate retail transactions. With its Proof of Stake (PoS) consensus method, Bitcoin Latinum ensures the network facilitates more transactions per minute at lower transaction fees. Utilizing an efficient consensus mechanism, Bitcoin Latinum provides a much better on-chain payment network compared to Bitcoin, with an average transaction confirmation in 3-5 seconds.LTNM is one of the greenest cryptocurrencies in existence, and recently joined the Crypto Climate Accord. Utilizing its advanced Proof of Stake (PoS) mechanism, LTNM holders will earn rewards for holding their coins as collateral to stake on the Bitcoin Latinum network. This leads to less electricity consumption. LTNM reduces the energy consumption to only 0.00015 kWh per transaction.For more information about Bitcoin Latinum, please visit https://bitcoinlatinum.comFOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. Any Bitcoin Latinum offered is for educational and informational purposes only and should NOT be construed as a securities-related offer or solicitation or be relied upon as personalized investment advice. Bitcoin Latinum strongly recommends you consult a licensed or registered professional before making any investment decision.Media contactBitcoin LatinumKai Okada, Director of CommunicationsE-mail: Kai.Okada@bitcoinlatinum.comWebsite: https://bitcoinlatinum.com/Telephone: +1 800-528-0985SOURCE: Bitcoin Latinum Copyright 2021 ACN Newswire. All rights reserved. (via SEAPRWire)

Fujitsu and France’s Inria Develop New Time-Series AI Technology to Identify Causes of Data Anomalies

TOKYO, Jul 16, 2021 - (JCN Newswire via SEAPRWire.com) - Fujitsu Limited and Inria, the French national research institute for digital science and technology, today announced the development of a new AI technology that can identify factors contributing to anomalies in time series data.Fig. 1 TDA-based technology for identifying the causes detecting anomaliesFig. 2 EEG data of delirium state (blue line) and EEG data judged to be normal generated by this technology (red line)In recent years, various kinds of time-series data collected in fields including healthcare, social infrastructure, and manufacturing have been leveraged by AI to perform situational judgment and detect anomalies. In the case of time-series data, however, there are a wide range of factors that can contribute to AI decision-making. This means that even experts find it difficult to notice what kind of changes in the data contributed to an anomaly detection making it difficult to take appropriate measures to prevent their occurrence.Fujitsu and Inria, more specifically the Inria's DATASHAPE Project Team led by Frederic Chazal in France, have now successfully developed a new technology based on Topological Data Analysis (TDA)(1) that can identify the factors contributing to anomaly detections by AI for time series data and visualize the differences in AI decisions during normal and anomalous circumstances.Fujitsu and Inria anticipate that this will contribute to the analysis of the causes of anomalies in time series data for various phenomena, clarifying the mechanism surrounding the occurrence of anomalies, as well as the discovery of new solutions to these.This technology will be presented as one of just 3% of total submitted papers as a "Long Talk" presentation at the Thirty-eighth International Conference on Machine Learning (ICML), the leading international conference in the field of machine learning, which opens virtually from July 18th, 2021.Newly Developed TechnologyFujitsu and Inria have developed an AI technology that can determine the cause of anomalies in time-series data, consisting of the following key features.1) Using an analysis technology developed by Fujitsu that extract features that affect judgement from time-series data and detects anomalies (2), the characteristics that led to the anomalous judgment as well as the unrelated characteristics from the data that was judged to be anomalous by the AI are mapped onto a plane (TDA space).2) The technology transforms the point data of the characteristic that is the cause closer to the point data group of the characteristic that is not the cause on the plane.3) The time-series data is deformed based on the conversion of the characteristics of the point data, and the data judged to be normal is generated.This allows the waveform of normal and anomalous time-series data to be compared and enables the user to visually investigate the cause of the anomaly. The newly developed technology was applied to test the possibility of detecting symptoms of delirium (3) using actual electroencephalography (EEG) data (4) collected in strict accordance with ethical guidelines. Using the newly developed technology, it was confirmed that the characteristics of the brain wave of the time series data coincided with the "slowing" phenomenon (5) that at times accompanies the state of delirium. These results offer the potential to help medical professionals interpret the data to help determine the cause of these symptoms. This may one day contribute to important medical developments, including the ability to discover possible precursors to diseases that have been difficult to identify with conventional techniques, as well as the discovery of preventive treatments. The technology could also be applied to shed light on the mechanisms of diseases that are not yet well-understood.Comments from Dr. Gen Shinozaki, ASSOCIATE PROFESSOR OF PSYCHIATRY AND BEHAVIORAL SCIENCES, Stanford University School of MedicineDue to the nature of the random signals, it has proven difficult to use EEG data quantitatively and accurately to identify certain disorders. In recent years, advances in data processing technologies, such as AI, have made it possible to better understand the characteristic changes in subtle brain waves. These advances are important not only for diagnosing various disorders, but also for understanding the treatment response and the pathophysiological mechanism. The technology developed by Fujitsu and Inria has successfully captured the unique characteristics of brain waves in patients suffering from delirium. In addition to verifying this, we anticipate that further improvement and practical use of this technology will ultimately offer the potential to achieve accurate diagnosis, monitoring of treatment response and the elucidation of pathophysiology for other disorders.Future PlansFujitsu and Inria plan to encourage the use of the jointly developed technology in field work and experiments at companies and research institutes, and proceed with verifying the technology.(1) Topological Data Analysis (TDA):A method for analyzing data in which data are arrayed in a cluster of points in space, and geometric data is extracted from the cluster.(2) an analysis technology developed by Fujitsu that classifies time-series data by features and detects anomalies:Fujitsu and France's Inria Jointly Develop Technology to Automatically Create Anomaly-Detecting AI Models (Press Release: 2020/3/16)(3) delirium:a syndrome, or group of symptoms, caused by a disturbance in the normal functioning of the brain. (4) actual EEG data:the newly developed technology was applied to the electroencephalographic data of approximately 600 patients, who consented to participate in research with Dr. Shinozaki, at the University of Iowa. Professor Shinozaki has been an Associate Professor at Stanford University since June 2021.(5) slowing phenomenon:a phenomenon that frequently occurs in the EEG data of patients suffering from delirium.About FujitsuFujitsu is the leading Japanese information and communication technology (ICT) company offering a full range of technology products, solutions and services. Approximately 126,000 Fujitsu people support customers in more than 100 countries. We use our experience and the power of ICT to shape the future of society with our customers. Fujitsu Limited (TSE:6702) reported consolidated revenues of 3.6 trillion yen (US$34 billion) for the fiscal year ended March 31, 2021. For more information, please see www.fujitsu.com. About InriaInria is the French national research institute for digital science and technology. World-class research, technological innovation and entrepreneurial risk are its DNA. In 200 project teams, most of which are shared with major research universities, more than 3,500 researchers and engineers explore new paths, often in an interdisciplinary manner and in collaboration with industrial partners to meet ambitious challenges.As a technological institute, Inria supports the diversity of innovation pathways: from open source software publishing to the creation of technological startups (Deeptech).www.inria.fr. Copyright 2021 JCN Newswire. All rights reserved. (via SEAPRWire)

Hitachi Launches ‘Hitachi Industrial Edge Computer CE series Embedded AI model’

TOKYO, Feb 1, 2021 - (JCN Newswire) - Hitachi, Ltd. (TSE: 6501) has announced the launch of "Hitachi Industrial Edge Computer CE series Embedded AI model", that was developed in collaboration with Intel Corporation. The product, an integration of Intel's AI technology and Hitachi's highly reliable control system design and manufacturing technologies, is a new model that incorporates an image analysis execution platform using AI and deep learning. Through providing this product, Hitachi contributes to the expansion of digital transformation, such as streamlining and automating tasks that rely on visual checks (the inspection process for finished products in the manufacturing industry) and solving management challenges using on-site data.Recently, the manufacturing industry and other industries have needed to urgently respond to intensified competition and increased complexity in the global market. Moreover, companies are facing many challenges, such as the need for the improvement of on-site work efficiency and the development of a new generation of expert workers, so they are implementing a digital transformation using IoT, AI, and other digital technologies. This trend has been accelerating amid the spread of the COVID-19 pandemic, especially with an urgent need for personnel allocation measures to maintain physical distance between workers on site. In order to fulfil these objectives, it is important to automate and conserve the labor used in visual inspections and other conventional inspections that rely on the sensory judgement of expert workers. Yet, in order for companies to enhance their competitiveness, rapid problem solving and decision making are also required by optimizing the entire production tasks and making effective use of management data through the collection, processing, and analysis of data from on-site devices.Against this backdrop, Hitachi collaborated with Intel and developed "Hitachi Industrial Edge Computer CE series Embedded AI model" as an edge computer that will enable the effective allocation of on-site workers and achieve automation and labor saving. With a built-in image analysis execution platform that uses Intel's AI and deep learning, the product will allow the easy introduction of solutions using AI functionality on site. For example, by incorporating an application that analyzes images from a variety of cameras installed on site and then determines whether the assembly work is being done correctly according to procedure, the product can reduce the need for manual inspection of finished goods, resulting in labor saving. In addition, data integration and data sharing with existing business systems can be performed on this product, with an application that collects data from a PLC(1) and other on-site devices, images of the on-site environment, and data related to power voltage, vibration, temperature and relative humidity. These enable rapid identification of the affected range in the event of defects, and the detection of environmental changes that may affect the quality of finished goods, contributing to the reduction of loss costs and improvement of the quality of finished goods. Furthermore, the product makes it possible to integrally monitor multiple remote production bases and lines, which is expected to optimize the production activities of companies.Intel's OpenVINO toolkit is pre-installed on the image analysis execution platform of this product to leverage AI and deep learning. By using a variety of pre-trained models that are optimized via the OpenVINO toolkit on the CPU, the detection of objects, estimation of structures, and other solutions using AI functionality that could not be achieved by conventional embedded devices can be easily performed. With its thermal design that encompasses Intel's Atom processor's low power consumption feature and Hitachi's knowhow gained through the development of Hitachi's information and control systems, the product achieves a fanless, slitness, and spindleless structure that can also be installed in harsh environments, such as manufacturing sites.Going forward, Hitachi will continue to collaborate with Intel's AI technologies and ecosystems, and will offer platform products that enable control using AI. Offering our products supporting Lumada, which is accelerating digital innovation, Hitachi will expand collaborative creation with our partner companies and customers, and will contribute to digital transformation in a wide range of fields across Japan and global.(1) Programmable Logic Controller (PLC): Control unit for a variety of machines in factories that was developed to replace relay logic systemsFor more information, visit http://www.hitachi.com/New/cnews/month/2021/02/210201.html. Copyright 2021 JCN Newswire. All rights reserved. www.jcnnewswire.com

PuduBot Gets a Job at an Australian BBQ Restaurant

MELBOURNE, Feb 1, 2021 - (ACN Newswire) - Recently, a famous Korean BBQ restaurant on Elizabeth Street in the CBD of Melbourne, Australia, took in a new member to deliver food in the store. That is PuduBot, the iconic delivery robot from Pudu Robotics.PuduBot has been well received by the locals since its introduction in the restaurant. While waiting for the food to be served, many customers use their mobile phones to take photos or videos of PuduBot hustling and bustling around.Robot waiters are nothing new in the modern world, but people may wonder "How does the robot deliver food to the designated location? How does it avoid people coming and going? Is it reliable? And how can it ensure the food is not spilled or dropped?"Well, it's all a piece of cake for PuduBot!PuduBot is developed by Pudu Robotics, a world-leading provider of commercial robots. The company is headquartered in Shenzhen, the global epicenter of hardware innovation, and has set up R&D centers in Shenzhen, Beijing and Chengdu, and hundreds of offices across the country. Pudu has developed over 400 patents, more than 60% of which are utility patents. Relying on the core technologies of low-speed autonomous driving, robotics motor, and motion control, Pudu has launched top-notch delivery and disinfection robots to the market.As we know, Pudu's delivery robot features automatic driving, positioning and navigation, and obstacle avoidance. So how does this work? It is made possible by the multi-sensor PUDU SLAM algorithm independently developed by Pudu. This cutting-edge technology integrates the data from the vision camera, lidar, RGBD camera, IMU, encoder, ultrasonic sensor and many more sensors, enabling centimeter-level map construction and positioning with high precision and robustness.When performing a task, the robot first identifies its own position and direction, makes global path planning based on the map and destination, and follows the calculated optimal path.During its movement, the robot processes data from sensors through the perception algorithm, accurately identifies obstacles in the environment, and generates a high-precision, multi-layer semantic map. It also makes local path planning to fine-tune the trajectory in real time while maintaining the general direction of the global path, allowing for flexible obstacle avoidance.Furthermore, thanks to the auto-level independent linkage suspension pioneered by Pudu Robotics, PuduBot provides sound damping performance comparable to vehicles, ensuring stable delivery of food and drink even when an obstacle is standing in the way.Most Pudu delivery robots come with a pleasingly simple appearance. Take PuduBot for example. Equipped with 3-4 trays, the body features a streamlined, lightweight design in colors of black and white, making it easier to blend into the environment. In the idle state, PuduBot presents cute and vivid expressions as appropriate on its navigation-sized screen.Today, Pudu's delivery robots have been sold all over the world. They have found wide applications in restaurants, hospitals, supermarkets, and even airports and office buildings of all sizes, providing flexible delivery that users can rely on.Media contactLinhong JiangPhone: +86-400-0826-660E-mail: global_sales@pudutech.comWebsite: https://pudurobotics.com/ Copyright 2021 ACN Newswire. All rights reserved. www.acnnewswire.com

Fujitsu Delivers Cashless, Contactless Retail Experience for Masked Shoppers with Hygienic, Multi-Factor Biometric Authentication Technology

KAWASAKI, Japan, Jan 21, 2021 - (JCN Newswire) - Fujitsu Laboratories, Ltd. has announced the development of a new multi-factor biometric authentication technology to deliver an innovative shopping experience for the "New Normal" era, combining non-contact biometrics that filter the verification target through facial data with identification performed via palm vein recognition. This technology enables identification with greater than 99% accuracy even when the user wears a mask, and will be showcased at a concept cashless Lawson convenience store at the Fujitsu Technology Square office in Shin-Kawasaki, Japan (1), for a field trial starting from January 2021.Fig. 1 Technology currently being verifiedFig. 2 Masks added to facial image dataFig. 3 Image of the updated user interfaceFig. 4 Multi-factor biometric authentication terminal in useUsers wearing masks present challenges to conventional facial recognition filtering technologies because a large part of the face is obscured, rendering authentication impossible in some cases. With the newly developed technology, however, differences in the appearance depending on the presence or absence of the mask can be absorbed by generating a composite image that combines the mask with the face image and training the model, achieving filtering accuracy of greater than 99%, or equivalent to that without a mask. Fujitsu has additionally enhanced its existing palm vein authentication sensor technology by improving the user interface so that users know how close to position their hand from the sensor for smooth authentication. This technology was ranked 6th amongst 147 participating global vendors and 1st place amongst Japanese vendors (2) in the face authentication vendor test conducted by the United States' National Institute of Standards and Technology (NIST).Development BackgroundIn recent years, the use of biometric authentication technologies has been increasing, including in areas like the processing of payments at brick-and-mortar stores and in ID verification for events. Now, these technologies also promise to help limit the spread of COVID-19 by limiting human contact during transactions and verification processes. To this end, Fujitsu is accelerating the introduction of contactless user interfaces for authentication leveraging facial and palm vein recognition with a variety of field trials over the past year (Fig. 1).ChallengesIn many parts of the world, mask-wearing has been highlighted by health officials as an important tool to help prevent the spread of infectious diseases like the COVID-19 virus. However, when face authentication is performed while wearing a mask, most of the face is hidden, and the accuracy of this method can sometimes deteriorate. With this in mind, Fujitsu has worked to improve the accuracy of multi-factor biometric authentication at its pilot store by combining facial filtering technology with palm vein recognition. In addition, when considering the introduction of the system for general users in brick-and-mortar stores going forward, it will become essential to improve the user interface of the system to improve user-friendliness, allowing users to register and authenticate themselves without complex explanations or intervention from store clerks.Newly Developed TechnologyFujitsu Laboratories has developed a data expansion machine learning technology that enables highly accurate filtering even when the target user is wearing a mask.The features of the developed technology are as follows.With typical facial recognition technology, when a user is wearing a mask only the exposed eye area is checked in order to extract features such as the shape and position of the face. While this method can help reduce the influence of wearing a mask over an accurate reading, it cannot extract the features of the entire face, presenting the possibility that the target user cannot be recognized due to insufficient data.In order to reduce this effect, the newly developed technology generates an image of the user's face without a mask while taking into account the extraction of features of the entire face, like its shape and contours. This means that even when the user is wearing a mask, the user can be recognized against the corresponding facial image can be narrowed down from a large database with the same level of accuracy as without a mask. Specifically, the technology estimates the position of the face based on facial features such as the position of the eyes and nose, and based on the estimation results, an artificial mask is resized and reshaped then superimposed over the face image to generate a natural masked facial image. In addition, the system uses various types of masks in order to deal with situations in which masks of various colors, patterns and shapes are worn by users (Fig. 2). This makes multi-factor authentication more hygienic and easier to use by allowing people to undergo authentication without removing their mask.Improved user interfaceThe user interface of the palm vein authentication system has also been improved to enable smoother use. A palm-shaped light has been added to the sensor, and the color and the pattern of the light changes according to the distance of the hand, so that the appropriate height for accurate authentication is apparent (Fig. 3). This allows people who are not familiar with palm vein authentication to adjust their palms to the appropriate height for smooth, contactless authentication (Fig. 4).OutcomesBy using the newly developed technology and user interface, Fujitsu hopes to provide safer and more secure services while preventing the spread of infectious diseases in a variety of situations, including payments at brick and mortar stores using biometric authentication and personal identification at leisure facilities.Future PlansTo make sure users can do the authentication process by themselves using the developed technology and improved UI, Fujitsu will introduce this technology to a system currently under verification(3) at a concept cashless Lawson convenience store in Shin-Kawasaki Technology Square in cooperation with Lawson, a major Japanese convenience store chain. Fujitsu will conduct verification tests from January 21, 2021 with the aim of putting the system into practical use by the end of FY 2021.(1) a concept cashless Lawson convenience store the Fujitsu Technology Square office in Shin-KawasakiSince February 2020, Fujitsu has been participating in a POC conducted by Lawson, Inc. for cashier-less solutions at a location in its offices. Based on the results of the POC, Lawson has been working with the Fujitsu as well as America's Zippin to identify business and technical issues.(2) This technology was ranked 6th amongst 147 participating global vendors and 1st place amongst Japanese vendorsIn the facial recognition vendor test conducted by the United States' NIST in November 2020. FRVT Face Mask Effects(3) Fujitsu will introduce this technology to a system currently under verificationRefers to system provided by VCOGNITION TECHNOLOGIES, INC "Zippin". The system integrates devices such as cameras and weight sensors necessary for automatic payment, AI functions for recognizing customers and products, and linking functions with payment and inventory management.About FujitsuFujitsu is the leading Japanese information and communication technology (ICT) company offering a full range of technology products, solutions and services. Approximately 130,000 Fujitsu people support customers in more than 100 countries. We use our experience and the power of ICT to shape the future of society with our customers. Fujitsu Limited (TSE:6702) reported consolidated revenues of 3.9 trillion yen (US$35 billion) for the fiscal year ended March 31, 2020. For more information, please see www.fujitsu.com.About Fujitsu LaboratoriesFounded in 1968 as a wholly owned subsidiary of Fujitsu Limited, Fujitsu Laboratories Ltd. is one of the premier research centers in the world. With a global network of laboratories in Japan, China, the United States and Europe, the organization conducts a wide range of basic and applied research in the areas of Next-generation Services, Computer Servers, Networks, Electronic Devices and Advanced Materials. For more information, please see: http://www.fujitsu.com/jp/group/labs/en/. Copyright 2021 JCN Newswire. All rights reserved. www.jcnnewswire.com

Eisai and Cogstate Expand Agreement for Global Development and Commercialization of Digital Cognitive Assessment Technologies

TOKYO, Oct 26, 2020 - (JCN Newswire) - Eisai Co., Ltd. and Cogstate, Ltd. announced today that the companies have entered into a collaboration whereby Eisai has secured the global development rights and exclusive commercialization rights of all cognitive function tests developed by Cogstate, including the "Cogstate Brief BatteryTM" (CBB) for use in healthcare and other markets. This global licensing deal is an expansion of an existing partnership executed in August 2019 whereby Eisai secured exclusive development and commercialization rights in Japan for all cognitive function tests developed by Cogstate, including the CBB. Both companies plan to proceed with development globally of CBB as a tool for individuals to self-assess brain performance to support healthy lifestyle choices and preventative measures in daily life, as well as a medical device to aid healthcare professionals in clinical diagnosis decisions. Developed by Cogstate, the CBB is a scientifically validated digital tool that enables cognitive function self-checks and consists of four tests evaluating psychomotor function, attention, learning and memory, and working memory. In the United States, Europe, Australia, New Zealand and Canada, the CBB has been adapted as a medical device named "CognigramTM" that has achieved marketing authorization by regulators in these jurisdictions and provides informative results for healthcare professionals to support clinical examination to aid in the diagnosis of MCI and dementia.In its medium-term business plan, EWAY2025, Eisai is aiming to become a "Medico Societal Innovator" (a company that changes society through creating medicines and providing solutions). Eisai is creating next-generation medical remedies focused on the neurology and oncology areas as well as building disease ecosystem platforms, in order to provide environments and solutions including digital solutions for early diagnosis and early treatment.Cogstate aims to make assessment of brain health as simple, common and informative as assessment of blood pressure. Cogstate's technology, which is easy to use and available in over 70 languages, is supported by extensive scientific validation, including more than 600 peer reviewed publications. Cogstate technology has been used extensively in clinical trials, including trials conducted by Eisai.The global agreement between Eisai and Cogstate will allow the two companies to replicate many of the advancements that have already been launched in Japan, where Eisai has developed and launched a new digital tool using the CBB, named "NouKNOWTM" (pronounced "NOH-NOH"), a non-medical device for self-assessment of brain performance (brain health). Eisai is currently investigating the possibility of developing a medical device using the CBB in Japan.In recent years, various research has demonstrated the possibility that decline in brain performance may be mitigated through major readjustments to lifestyle, such as regular exercise and sleep, a well-balanced diet, and social interaction. However, according to a survey by Eisai, the number of people taking correct preventive actions or habitually performing self-checks of cognitive function are few, with disparities (chasms) existing against the incorporation of these habits into daily lifestyle.As a result of these findings, in Japan, Eisai is constructing a dementia platform, called "Easiit", with the goal of erasing these chasms. Core to this platform will be the brain-performance self-check tool "NouKNOW" and the "Easiit App" which aims to contribute to the promotion of health practices through data visualization of brain and body health insights.It can be expected that the use of "NouKNOW" to perform periodic self-assessments of brain performance among the generation currently in their prime working years, along with the use of the "Easiit App" for the adjustment of lifestyle and practice of preventive measures in daily life, will become an opportunity for the creation of better brain and body health.Through this agreement, Eisai and Cogstate will work together for the development of digital tools for simpler self-checks of cognitive function and diagnostic tool development for healthcare professionals to promote greater awareness of brain performance globally, thus contributing to the realization of well-being for all.About Eisai Co., Ltd.Eisai Co., Ltd. defines our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care (hhc) philosophy. With approximately 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our hhc philosophy by delivering innovative products to address unmet medical needs, with a particular focus in our strategic areas of Neurology and Oncology. As a global pharmaceutical company, our mission extends to patients around the world through working with key stakeholders to improve access to medicines in developing and emerging countries.For further information on Eisai Co., Ltd., please visit https://www.eisai.comAbout Cogstate Ltd.Cogstate Ltd. (ASX:CGS) is a neuroscience technology company headquartered in Melbourne, Victoria, Australia and New Haven, Connecticut, USA, focused on optimising brain health assessments to advance the development of new medicines and to enable earlier clinical insights in healthcare. Since 1999, Cogstate technologies have provided rapid, reliable and highly sensitive computerised cognitive tests across a growing list of domains. The company's clinical trials solutions include quality assurance services for clinical outcome assessments that combine electronic data capture, innovative operational approaches, advanced analytics and scientific consulting. For more than 20 years, Cogstate has proudly supported the leading-edge research needs of biopharmaceutical companies and academic institutions and the clinical care needs of physicians and patients around the world. Notwithstanding this agreement, Cogstate will continue to independently offer its technology and services to the clinical trials market.For further information on Cogstate, please visit www.cogstate.com.Eisai Co., Ltd.Public Relations DepartmentTEL : +81-(0)3-3817-5120Cogstate, Ltd.Rachel Colite: rcolite@cogstate.comNatalie Hasapaki: nhasapaki@we-worldwide.com Copyright 2020 JCN Newswire. All rights reserved. www.jcnnewswire.com